FDA accepts Lexicon's heart failure resubmission; Bristol Myers buys out mavacamten royalties
Just two weeks after the FDA again denied Lexicon Pharmaceuticals’ attempt to overturn a CRL in type 1 diabetes, the Texas biotech said the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
